Atlas Trials

A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma

Clinical trial NCT06296121 · UNKNOWN

Trial details

NCT number
NCT06296121
Sponsor
Biocad
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2023-12-21
Primary completion
2025-01-01
Enrollment
252

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.